CDW (CDW)’s Insider Neal Campbell Sells 3,805 Shares of the Company; Last Week TG Therapeutics, Inc. (TGTX) Analysts

CDW Corporation (NASDAQ:CDW) Logo

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Friday, March 9. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, March 21. On Thursday, October 6 the stock rating was reinitiated by Brean Capital with “Buy”. The rating was maintained by Raymond James on Thursday, April 19 with “Buy”. B. Riley & Co maintained TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Friday, December 1. B. Riley & Co has “Buy” rating and $21.5 target. The firm earned “Buy” rating on Tuesday, March 7 by H.C. Wainwright. The firm has “Buy” rating by Suntrust Robinson given on Friday, May 27. The company was initiated on Tuesday, December 1 by FBR Capital. The stock has “Buy” rating by Jefferies on Monday, June 5. The firm earned “Buy” rating on Monday, June 4 by FBR Capital. See TG Therapeutics, Inc. (NASDAQ:TGTX) latest ratings:

04/06/2018 Broker: FBR Capital Rating: Buy New Target: $25.0000 Maintain
19/04/2018 Broker: Raymond James Rating: Buy Maintain
21/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Initiate
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $27.0 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
17/01/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain

Investors sentiment decreased to 1.46 in 2018 Q1. Its down 0.54, from 2 in 2017Q4. It dropped, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported. Putnam Investments Ltd holds 92,543 shares. Baldwin Brothers Ma reported 17,850 shares. First Mercantile has invested 0.08% in TG Therapeutics, Inc. (NASDAQ:TGTX). Credit Suisse Ag has invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Stoneridge Invest Prns Limited Liability accumulated 0.13% or 56,176 shares. Citadel Advsr Limited Liability Corporation holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 189,915 shares. Vantage Advsrs Ltd Liability Com reported 150 shares. Exane Derivatives holds 0% or 9,834 shares. The Massachusetts-based Ra Cap Mngmt Ltd Co has invested 2.69% in TG Therapeutics, Inc. (NASDAQ:TGTX). 464,391 were reported by Highland Mgmt Limited Partnership. Deutsche National Bank Ag holds 56,252 shares. Geode Cap Ltd Liability holds 498,251 shares or 0% of its portfolio. Trexquant Investment Ltd Partnership holds 85,943 shares. 23,304 are held by Barclays Pcl. Price T Rowe Assocs Md invested in 0% or 39,736 shares.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.08 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: which released: “TG Therapeutics: An Immunology Powerhouse” on June 14, 2018, also with their article: “TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer” published on June 04, 2018, published: “TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with …” on June 18, 2018. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: and their article: “TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K …” published on June 18, 2018 as well as‘s news article titled: “TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European …” with publication date: June 15, 2018.

The stock increased 1.09% or $0.15 during the last trading session, reaching $13.95. About 844,118 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since June 20, 2017 and is uptrending. It has outperformed by 2.14% the S&P500. Some Historical TGTX News: ; 18/04/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor; 08/03/2018 – TG THERAPEUTICS INC QUARTERLY LOSS PER COMMON SHARE $0.46; 08/03/2018 – TG Therapeutics 4Q Loss $30.9M; 08/05/2018 – TG THERAPEUTICS-CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AS OF MARCH 31, SUFFICIENT TO FUND OPERATIONS THROUGH MID-2019; 08/05/2018 – TGTX TO REPORT FILING DECISION ON FIRST BLA/NDA LATER IN YEAR; 06/03/2018 TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update; 17/05/2018 – TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association; 07/04/2018 – TG Therapeutics Access Event Scheduled By B. Riley FBR, Inc; 15/05/2018 – Ra Capital Management Buys New 3.2% Position in TG Therapeutics; 08/05/2018 – TG Therapeutics 1Q Loss $41.5M

Since December 29, 2017, it had 0 insider purchases, and 2 selling transactions for $609,256 activity. $337,205 worth of TG Therapeutics, Inc. (NASDAQ:TGTX) shares were sold by KENNEDY WILLIAM JAMES. Power Sean A sold $272,051 worth of stock.

Since January 8, 2018, it had 0 buys, and 26 sales for $18.89 million activity. CORLEY CHRISTINA M had sold 4,000 shares worth $271,240 on Tuesday, February 13. Another trade for 8,542 shares valued at $669,437 was sold by CAMPBELL NEAL J. The insider Richards Thomas E sold $1.00M. KULEVICH FREDERICK J. sold $303,558 worth of stock or 4,251 shares. 7,702 CDW Corporation (NASDAQ:CDW) shares with value of $528,199 were sold by ROTHER CHRISTINA V. $51,982 worth of CDW Corporation (NASDAQ:CDW) was sold by FAIRFIELD NEIL B on Friday, March 9. Another trade for 17,500 shares valued at $1.47M was sold by LEAHY CHRISTINE A.

Another recent and important CDW Corporation (NASDAQ:CDW) news was published by which published an article titled: “CDW to Present at the NASDAQ 38th Investor Conference” on May 30, 2018.

The stock decreased 0.38% or $0.32 during the last trading session, reaching $84.72. About 1.42M shares traded or 80.04% up from the average. CDW Corporation (NASDAQ:CDW) has risen 35.86% since June 20, 2017 and is uptrending. It has outperformed by 23.29% the S&P500. Some Historical CDW News: ; 02/05/2018 – CDW EXPECTS TO EXCEED ANNUAL IT MARKET GROWTH TARGET; 02/05/2018 – CDW 1Q Net $127M

Among 12 analysts covering CDW (NASDAQ:CDW), 7 have Buy rating, 1 Sell and 4 Hold. Therefore 58% are positive. CDW has $85.0 highest and $43 lowest target. $64.92’s average target is -23.37% below currents $84.72 stock price. CDW had 39 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of CDW Corporation (NASDAQ:CDW) has “Outperform” rating given on Tuesday, August 4 by RBC Capital Markets. Robert W. Baird maintained the stock with “Buy” rating in Thursday, August 3 report. The rating was maintained by Stifel Nicolaus on Wednesday, October 14 with “Buy”. The stock of CDW Corporation (NASDAQ:CDW) earned “Equal-Weight” rating by Barclays Capital on Monday, July 24. On Monday, July 17 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Thursday, August 6, the company rating was upgraded by Zacks. The stock has “Buy” rating by Deutsche Bank on Sunday, September 6. Raymond James maintained CDW Corporation (NASDAQ:CDW) on Tuesday, August 4 with “Buy” rating. RBC Capital Markets maintained the shares of CDW in report on Tuesday, August 1 with “Buy” rating. Robert W. Baird upgraded CDW Corporation (NASDAQ:CDW) on Tuesday, May 9 to “Outperform” rating.

Analysts await CDW Corporation (NASDAQ:CDW) to report earnings on August, 2. They expect $1.22 earnings per share, up 24.49% or $0.24 from last year’s $0.98 per share. CDW’s profit will be $185.15 million for 17.36 P/E if the $1.22 EPS becomes a reality. After $1.04 actual earnings per share reported by CDW Corporation for the previous quarter, Wall Street now forecasts 17.31% EPS growth.

The insider, and Cdw Corp’s See Remarks, Neal Campbell, sold 3,805 company shares on 19-06-2018, worth around $312,958 (at $82.2 for every share). Now, Neal Campbell owns 24,859 shares which make up about 0.02% of the company’s total market cap.

Investors sentiment increased to 1.18 in 2018 Q1. Its up 0.15, from 1.03 in 2017Q4. It increased, as 31 investors sold CDW Corporation shares while 126 reduced holdings. 59 funds opened positions while 126 raised stakes. 134.05 million shares or 1.41% less from 135.97 million shares in 2017Q4 were reported. The United Kingdom-based Lloyds Grp Public Ltd Com has invested 1.08% in CDW Corporation (NASDAQ:CDW). Capital Fund Mgmt Sa has invested 0.02% in CDW Corporation (NASDAQ:CDW). Axa holds 0.01% in CDW Corporation (NASDAQ:CDW) or 18,481 shares. Manufacturers Life Insur The accumulated 201,312 shares or 0.02% of the stock. Teachers Retirement Of The State Of Kentucky, Kentucky-based fund reported 141,004 shares. Andra Ap accumulated 127,700 shares. Sg Americas Limited Liability Com accumulated 0.01% or 10,985 shares. Polaris Greystone Group Inc Limited Liability owns 321,765 shares. Sandhill Prtnrs Limited Liability Corporation holds 3.11% or 269,156 shares. Virginia Retirement Et Al has 349,100 shares for 0.3% of their portfolio. Riverhead Cap owns 3,050 shares. American Int Group, a New York-based fund reported 7,905 shares. Secor Advsrs Lp holds 0.17% or 29,526 shares in its portfolio. Hussman Strategic reported 25,000 shares or 0.49% of all its holdings. Strs Ohio holds 0% or 9,575 shares in its portfolio.

CDW Corporation (NASDAQ:CDW) Institutional Positions Chart